Innovation in Gene Therapy Starts at UPMC Children’s
UPMC Children’s is on its way to becoming the lead site for development and human clinical trials of a new gene therapy treatment for VLCADD (Very Long Chain Acyl CoA Dehydrogenase Deficiency), a rare genetic disorder that is identified through newborn screening.